MORPHOSYS AG O.N. news, videos and press releases - Page 7
For more news please use our advanced search feature.
MORPHOSYS AG O.N. - More news...
MORPHOSYS AG O.N. - More news...
- DGAP-Adhoc: Ad hoc: MorphoSys AG preliminary results for the fiscal year 2020 exceeding guidance
- Morphosys AG Preliminary Results for the Fiscal Year 2020 Exceeding Guidance
- DGAP-News: MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
- MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
- DGAP-News: MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
- MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
- DGAP-News: MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
- DGAP-News: MorphoSys Appoints Sung Lee as Chief Financial Officer
- DGAP-News: MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
- DGAP-News: MorphoSys AG: Corporate Calendar 2021
- MorphoSys AG: Corporate Calendar 2021
- DGAP-News: Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
- DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
- DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
- DGAP-News: Thomas Biegi Joins MorphoSys as Head of Corporate Communications
- Thomas Biegi Joins MorphoSys As Head of Corporate Communications
- DGAP-News: MorphoSys Reports Nine Months and Third Quarter 2020 Results
- DGAP-News: MorphoSys and Cherry Biolabs Announce licensing of Hemibody Technology
- DGAP-News: Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
- MorphoSys Reports Nine Months and Third Quarter 2020 Results
- MorphoSys and Cherry Biolabs Announce Licensing of Hemibody Technology
- DGAP-News: MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition
- DGAP-News: Invitation to MorphoSys' Third Quarter and First 9-Month 2020 Results Conference Call on November 12, 2020
- MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition
- Invitation to MorphoSys' Third Quarter and First 9-Month 2020 Results Conference Call on November 12, 2020
- DGAP-Adhoc: Ad hoc: MorphoSys AG Raises its Financial Guidance for the Full Year 2020
- MorphoSys AG Raises its Financial Guidance for the Full Year 2020
- DGAP-News: MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)
- MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)
- DGAP-News: MorphoSys AG Successfully Places EUR 325 Million Convertible Bonds
